{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=13", "query": { "condition": "Recurrent", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 9639, "total_pages": 964, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T07:47:41.617Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00654953", "title": "Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Dependence", "Depressive Symptoms" ], "interventions": [ { "name": "sertraline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "gabapentin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 102, "start_date": "2006-01", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-04-25", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654953" }, { "nct_id": "NCT03387020", "title": "Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CNS Embryonal Tumor, Not Otherwise Specified", "Malignant Glioma", "Recurrent Atypical Teratoid/Rhabdoid Tumor", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 22, "start_date": "2018-01-13", "completion_date": "2020-04-01", "has_results": true, "last_update_posted_date": "2021-08-27", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387020" }, { "nct_id": "NCT00823459", "title": "Everolimus in Treating Patients With Recurrent Low-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Diffuse Astrocytoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Subependymal Giant Cell Astrocytoma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Archival Tissue Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susan Chang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2009-01-23", "completion_date": "2017-11-13", "has_results": true, "last_update_posted_date": "2020-07-28", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823459" }, { "nct_id": "NCT00126503", "title": "Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2005-05", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2015-01-15", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126503" }, { "nct_id": "NCT00392769", "title": "Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 33, "start_date": "2006-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-09-06", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392769" }, { "nct_id": "NCT00569673", "title": "Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trabectedin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 71, "start_date": "2008-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 37, "location_summary": "Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569673" }, { "nct_id": "NCT01395537", "title": "Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction" ], "interventions": [ { "name": "Carboplatin AUC", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-08", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-03-19", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01395537" }, { "nct_id": "NCT01846520", "title": "Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Subject", "Localized Transitional Cell Cancer of the Renal Pelvis and Ureter", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Psychosocial Effects of Cancer and Its Treatment", "Recurrent Bladder Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Gastric Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Uterine Sarcoma", "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter", "Stage II Bladder Cancer", "Stage II Renal Cell Cancer", "Stage II Urethral Cancer", "Stage IIA Cervical Cancer", "Stage IIA Colon Cancer", "Stage IIA Gastric Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIA Uterine Sarcoma", "Stage IIB Cervical Cancer", "Stage IIB Colon Cancer", "Stage IIB Gastric Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIB Uterine Sarcoma", "Stage IIC Colon Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIC Rectal Cancer", "Stage III Bladder Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage III Urethral Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Rectal Cancer", "Stage IIIA Uterine Sarcoma", "Stage IIIB Cervical Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Rectal Cancer", "Stage IIIB Uterine Sarcoma", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Rectal Cancer", "Stage IIIC Uterine Sarcoma", "Stage IV Bladder Cancer", "Stage IV Gastric Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IV Urethral Cancer", "Stage IVA Cervical Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Uterine Sarcoma", "Stage IVB Cervical Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Stage IVB Uterine Sarcoma", "Ureter Cancer", "Stage IIA Lung Carcinoma", "Stage IIB Lung Carcinoma", "Stage IIIA Lung Carcinoma", "Stage IIIB Lung Carcinoma" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2013-10-29", "completion_date": "2019-05-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846520" }, { "nct_id": "NCT00045188", "title": "Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045188" }, { "nct_id": "NCT06590961", "title": "UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Malignancies" ], "interventions": [ { "name": "UBX-303061", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ubix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2025-02-20", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-17T07:47:41.617Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Canton, Oklahoma • Houston, Texas", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Canton", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06590961" } ] }